• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Section Contents Menu

Enforcement Actions

Intelligent Nutrients, Inc. 20-Aug-02

Department of Health and Human ServicesDepartment of Health and Human Services            Public Health Service


Food and Drug Administration

Minneapolis District

240 Hennepin Avenue

Minneapolis MN 55401-1999

Telephone, 612-334-4100

August 20, 2002

WARNING LETTER

CERTIFIED MAIL

RETURN RECEIPT REQUESTED

Horst Rechelbacher

Owner

Intelligent Nutrients, Inc.

321 Lincoln Street NE

Minneapolis, Minnesota 55413

Refer to MIN 02 - 443

Dear Mr. Rechelbacher:

This letter is written in reference to your marketing of the product "Daily Elixir™ First Aid Mixative." The Food and Drug Administration (FDA) collected samples of this product at your 321 Lincoln Street, Minneapolis, MN, location. An analysis of the "Daily Elixir™ First Aid Mixative" revealed the actual level of Selenium in the product to be significantly less than listed on the label. The product is labeled to contain 50 mcg or 70% of the Percent Daily Value per 0.07 ounce packet. However, FDA analysis of the two samples of your product found that it contained less than 80% of the amount declared on the label.

This causes your product to be adulterated within the meaning of Section 402(b)(1) of the Federal Food, Drug and Cosmetic Act (the Act) in that a valuable constituent, Selenium, has been in part omitted or abstracted therefrom.

This also causes your product to be misbranded under Section 403(a)(l) of the Act because the product labeling is false and misleading in that Selenium has been in part omitted.

We request that you notify this office in writing within, 15 working days of receipt of this letter stating the actions you will take to correct the violations and to prevent their recurrence. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed.

Failure to make prompt corrections may result in further enforcement action being initiated by the FDA. This could include seizure of illegal products and injunction against the manufacturer and/or distributor of illegal products.

This letter does not represent a comprehensive review of all of the products distributed by your firm, nor does it represent a complete review of all product labeling, which may include product brochures, product catalogs, newsletters and Internet web sites, as applicable. As owner, it is your responsibility to ensure that all products distributed by your firm are in compliance with the Act and itsimplementing regulations.

Your reply should be directed to Compliance Officer Tyra S. Wisecup at the address indicated in the letterhead. Ms. Wisecup may be reached at (612) 334-4100 ext. 124.

Sincerely,

/s/

Annette Byrne

Acting Director

Minneapolis District